Ohr Pharma raises $18m to build ophthalmology portfolio
This article was originally published in Scrip
Executive Summary
Ohr Pharmaceuticals is raising $18m, through the sale of 1.8 million shares of common stock, in order to finance its current clinical trials and seek out "additional innovative ophthalmic candidates."